Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
DJ Angiolillo, A Fernandez-Ortiz, E Bernardo… - Journal of the American …, 2007 - jacc.org
Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …
Intracoronary optical coherence tomography: a comprehensive review: clinical and research applications
Cardiovascular optical coherence tomography (OCT) is a catheter-based invasive imaging
system. Using light rather than ultrasound, OCT produces high-resolution in vivo images of …
system. Using light rather than ultrasound, OCT produces high-resolution in vivo images of …
Molecular basis of restenosis and drug-eluting stents
MA Costa, DI Simon - Circulation, 2005 - Am Heart Assoc
Next is a granulation or cellular proliferation phase. Growth factors are subsequently
released from platelets, leukocytes, and SMCs, which stimulate migration of SMCs from the …
released from platelets, leukocytes, and SMCs, which stimulate migration of SMCs from the …
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working …
GJ Tearney, E Regar, T Akasaka… - Journal of the American …, 2012 - jacc.org
Objectives: The purpose of this document is to make the output of the International Working
Group for Intravascular Optical Coherence Tomography (IWG-IVOCT) Standardization and …
Group for Intravascular Optical Coherence Tomography (IWG-IVOCT) Standardization and …
Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional …
JE Sousa, MA Costa, A Abizaid, AS Abizaid, F Feres… - Circulation, 2001 - Am Heart Assoc
Background—Restenosis remains an important limitation of interventional cardiology.
Therefore, we aimed to determine the safety and efficacy of sirolimus (a cell-cycle inhibitor) …
Therefore, we aimed to determine the safety and efficacy of sirolimus (a cell-cycle inhibitor) …
Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up
JE Sousa, MA Costa, AC Abizaid, BJ Rensing… - Circulation, 2001 - Am Heart Assoc
Background We have previously reported a virtual absence of neointimal hyperplasia 4
months after implantation of sirolimus-eluting stents. The aim of the present investigation …
months after implantation of sirolimus-eluting stents. The aim of the present investigation …
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
DJ Angiolillo, A Fernandez-Ortiz, E Bernardo… - Diabetes, 2005 - Am Diabetes Assoc
To assess platelet function profiles in diabetic and nondiabetic patients on aspirin and
clopidogrel therapy, two patient populations were included to investigate the 1) acute effects …
clopidogrel therapy, two patient populations were included to investigate the 1) acute effects …
Intramyocardial, autologous CD34+ cell therapy for refractory angina
DW Losordo, TD Henry, C Davidson, J Sup Lee… - Circulation …, 2011 - Am Heart Assoc
Rationale: A growing number of patients with coronary disease have refractory angina.
Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous …
Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous …
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet …
DJ Angiolillo, SB Shoemaker, B Desai, H Yuan… - Circulation, 2007 - Am Heart Assoc
Background—After treatment with clopidogrel, patients with type 2 diabetes mellitus (T2DM)
have reduced platelet inhibition compared with patients who are not diabetic. Whether …
have reduced platelet inhibition compared with patients who are not diabetic. Whether …
New frontiers in cardiology: drug-eluting stents: Part I
JE Sousa, PW Serruys, MA Costa - Circulation, 2003 - Am Heart Assoc
various coatings at different time intervals. The achievement of a hospitable relationship
between stent, coating matrix, drug, and vessel wall is extremely challenging. In principle …
between stent, coating matrix, drug, and vessel wall is extremely challenging. In principle …